Role of sphingosine synthesis inhibition in transcutaneous delivery of levodopa

被引:8
作者
Babita [1 ]
Gupta, S [1 ]
Tiwary, AK [1 ]
机构
[1] Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Patiala 147002, Punjab, India
关键词
skin sphingosine; beta-chloroalanine; percutaneous permeation; levodopa;
D O I
10.1016/S0378-5173(02)00063-7
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The present study was designed to investigate the role of skin sphingosine synthesis inhibition in enhancing the in vitro permeation of levodopa (LD), a hydrophilic drug, across rat skin. P-Chloroalanine (P-CA), a selective inhibitor of serine palmitoyl transferase was used for inhibiting sphingosine synthesis in viable skin. The sphingosine content in viable skin perturbed by acetone treatment and immediately treated with P-CA (600 or 1200 mug/7 cm(2)) was significantly less than that of perturbed viable skin after 36 h of treatment (P < 0.001). The in vitro permeation of LD across perturbed-beta-CA treated skin was significantly greater than that across perturbed skin (P < 0.001). This indicates an inverse relationship between in vitro permeation of LD and skin sphingosine content. The systemic delivery of percutaneously applied LD across normal rat skin was negligible. Higher C-max, lower T-max, and maintenance of effective plasma concentration of LD over 28 h was achieved by a single topical application of carbidopa-LD combination (1:4) to perturbed-beta-CA treated skin. Hence, skin sphingosine synthesis inhibition can be used as a novel means of enhancing systemic delivery of LD. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:43 / 50
页数:8
相关论文
共 24 条
[1]
Omega-hydroxyceramides are required for corneocyte lipid envelope (CLE) formation and normal epidermal permeability barrier function [J].
Behne, M ;
Uchida, Y ;
Seki, T ;
de Montellano, PO ;
Elias, PM ;
Holleran, WM .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 114 (01) :185-192
[2]
TRANSDERMAL DELIVERY OF LEVONORGESTREL .8. EFFECT OF ENHANCERS ON RAT SKIN, HAIRLESS MOUSE SKIN, HAIRLESS GUINEA-PIG SKIN, AND HUMAN SKIN [J].
CATZ, P ;
FRIEND, DR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 58 (02) :93-102
[3]
INFLUENCE OF ROUTE OF ADMINISTRATION ON PHYSIOLOGICAL AVAILABILITY OF LEVODOPA IN DOGS [J].
COTLER, S ;
HOLAZO, A ;
BOXENBAUM, HG ;
KAPLAN, SA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1976, 65 (06) :822-827
[4]
PHOTOMETRIC DETERMINATION OF EPINEPHRINE IN PHARMACEUTICAL PRODUCTS [J].
DOTY, JR .
ANALYTICAL CHEMISTRY, 1948, 20 (12) :1166-1168
[5]
ELIAS PM, 1991, ADV LIPID RES, V24, P1
[6]
CHOLESTEROL-SYNTHESIS IS REQUIRED FOR CUTANEOUS BARRIER FUNCTION IN MICE [J].
FEINGOLD, KR ;
MAN, MQ ;
MENON, GK ;
CHO, SS ;
BROWN, BE ;
ELIAS, PM .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (05) :1738-1745
[7]
GAMEZ R, 1976, ANAL PROFILES DRUG S, V5, P189
[8]
INTESTINAL DECARBOXYLATION OF L-DOPA IN RELATION TO DOSE REQUIREMENT IN PARKINSONS-DISEASE [J].
GRANERUS, AK ;
JAGENBURG, R ;
SVANBORG, A .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1973, 280 (04) :429-439
[9]
SPHINGOLIPIDS ARE REQUIRED FOR MAMMALIAN EPIDERMAL BARRIER FUNCTION - INHIBITION OF SPHINGOLIPID SYNTHESIS DELAYS BARRIER RECOVERY AFTER ACUTE PERTURBATION [J].
HOLLERAN, WM ;
MAN, MQ ;
WEN, NG ;
MENON, GK ;
ELIAS, PM ;
FEINGOLD, KR .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (04) :1338-1345
[10]
HOLLERAN WM, 1991, J LIPID RES, V32, P1151